The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) | RFA DK 21 004

Frequently Asked Questions (FAQs)

What is the title of this grant opportunity?

The opportunity is titled "The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional)."

What is the main scientific focus of this FOA?

The FOA supports original research on how the immune system recognizes and responds to autoantigens and, especially, neoantigens in type 1 diabetes (T1D). A central theme is that newly formed or altered protein fragments (neoepitopes) may arise and contribute to autoimmune attack on pancreatic beta cells.

What are neoantigens and neoepitopes in the context of this announcement?

In this FOA, neoantigens/neoepitopes refer to newly formed or altered fragments of proteins that can be created by processes such as post-translational modifications. These changes may make a normal self-protein appear "new" to the immune system and potentially drive autoimmune responses in T1D.

Why does the FOA emphasize post-translational modifications?

The announcement highlights post-translational modifications because chemical changes to proteins after they are produced may influence immune recognition. The FOA encourages studies that connect these molecular alterations to immune function, including effects on autoantibodies and T cell responses.

What types of immune responses are applicants encouraged to study?

The FOA specifically encourages research that examines both humoral immunity (such as autoantibodies) and cell-mediated immunity (such as T cell responses), particularly as they relate to modified beta cell proteins and neoepitopes.

Does the FOA support studies on how neoantigens are generated and presented to the immune system?

Yes. The FOA describes interest in practical, mechanistic questions such as how modified beta cell proteins are generated, how they are processed and presented by antigen-presenting cells, and whether they provoke stronger or different autoimmune responses than unmodified proteins.

Is discovery of new neoantigens or neoepitopes enough to be competitive?

No. While discovery can be included, the FOA states that discovery alone is not sufficient. Applications should demonstrate functional relevance and explain how identified neoepitopes/neoantigens contribute to the etiology and pathophysiology of T1D.

What does "functional relevance" mean in this FOA?

Based on the FOA description, functional relevance means going beyond listing or cataloging new targets. Applicants are expected to clarify what neoepitopes and neoantigens do in disease, how they shape immune responses, and how they fit into the biology of T1D onset and progression.

How should new neoantigen findings be related to established T1D targets?

The FOA expects applicants to integrate new findings with established knowledge about known T1D antigens and epitopes. It specifically references well-characterized targets and biomarker systems, indicating new work should be interpreted alongside standard markers rather than treated in isolation.

Which established T1D autoantibody targets are specifically referenced?

The FOA references autoantibodies to insulin, GAD65, IA-2, and ZnT8 as well-characterized targets and biomarker systems that should inform interpretation of new neoantigen work.

What kinds of linkages to the broader T1D landscape does the FOA encourage?

The FOA indicates that strong proposals would likely explain how newly identified modified epitopes relate to known immune signatures, disease staging, genetic risk, or clinical phenotype, and how they might complement or refine current models of immune recognition in T1D.

What are the longer-term translational goals described in the FOA?

The FOA frames longer-term objectives around improving disease monitoring and enabling more personalized care. By understanding which neoantigens matter, when they appear, and how they correlate with immune activation or beta cell stress, the research is expected to lay groundwork for better tools to track progression, evaluate treatment response, and stratify patients into meaningful subgroups.

Does the FOA mention personalized therapeutics?

Yes. It points toward potential personalized therapeutics and implies interest in research that could eventually support individualized immune monitoring panels, antigen-specific tolerance strategies, or targeted interventions based on an individual antigen/neoantigen profile.

What grant mechanism is used for this opportunity?

The FOA uses the NIH R01 mechanism.

Are clinical trials required?

No. The FOA is labeled "Clinical Trial Optional," meaning projects can be purely mechanistic and preclinical or include clinical components when appropriate, as long as they remain aligned with the neoantigen and functional immunology focus.

What is the Funding Opportunity Number (FOA number)?

The Funding Opportunity Number is RFA DK 21 004.

Which agency is offering this opportunity?

This is a National Institutes of Health (NIH) funding opportunity.

What are the CFDA numbers associated with this opportunity?

The CFDA numbers listed are 93.847 and 93.855.

What is the listed award ceiling?

The listed award ceiling is 500000.

What were the key dates provided?

The FOA creation date is March 17, 2021, and the original closing date was March 9, 2022.

Who is eligible to apply?

Eligibility is broad and includes many types of domestic applicants, such as state and local governments, public and private institutions of higher education, nonprofits (with or without 501(c)(3) status), for-profit organizations other than small businesses, and small businesses.

Are small businesses eligible?

Yes. Small businesses are explicitly included among eligible applicants.

Are for-profit organizations eligible?

Yes. For-profit organizations other than small businesses are included among eligible applicants.

Are nonprofit organizations eligible even if they do not have 501(c)(3) status?

Yes. The FOA includes nonprofits with or without 501(c)(3) status.

Are institutions that serve specific communities explicitly encouraged or listed as eligible?

Yes. The FOA explicitly highlights additional eligible applicants and community-relevant institutions, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, and Tribally Controlled Colleges and Universities.

Are tribal governments eligible?

Yes. The FOA includes Indian or Native American tribal governments, and it also references tribal governments (including those other than federally recognized) in the "other eligible applicants" list.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are explicitly listed among eligible applicants.

Are U.S. territories or possessions eligible?

Yes. U.S. territories or possessions are listed among eligible applicants.

Are non-U.S. entities (foreign organizations) eligible to apply?

Yes. Non-U.S. entities (foreign organizations) are explicitly included in the eligibility description provided.

What is the overarching purpose of the FOA as described?

Overall, the FOA is designed to broaden participation while advancing a detailed, functionally grounded understanding of how modified self-antigens may drive autoimmunity in T1D, with the end goal of improving monitoring tools and enabling more personalized approaches to prevention and treatment.